FDA 483 - Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC - September 19, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC in Andover, MA, a biological drug substance manufacturer, was cited with three observations during an FDA inspection. The observations highlight significant concerns regarding process control, including the exclusion of continuous process verification data, inadequate temperature control for drug substance shipping, and an unjustified "non-CQA" designation for a critical attribute, indicating potential risks to product safety and efficacy.
- Inspection Date
- September 19, 2023
- Product Type
- Biologics
ID · 7326d811-b200-4ac7-ae4e-783a9762d90c